Aspirin and the Treatment of Rheumatoid Arthritis

Csuka, Mary Ellen; McCarty, Daniel J.

doi:10.1016/s0889-857x(21)01002-4

Cited by 11 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aspirin is also the drug of choice for prophylaxis in revascularization surgeries including coronary bypass surgery (Members, Eagle et al, 2004 ; Smith et al, 2006 ). While being initially widely used, aspirin’s use in rheumatic diseases such as rheumatoid arthritis has declined for two reasons: 1) its anti-inflammatory properties are established at relatively high doses, and 2) the desired effects are reached at lower doses with more efficacy with non-salicylate nonsteroidal anti-inflammatory drugs (NSAIDs) ( Csuka and McCarty, 1989 ). Despite that, aspirin is still part of the treatment Kawasaki disease ( Rife and Gedalia, 2020 ).…”

Section: Clinical Uses Of Aspirinmentioning

confidence: 99%

Aspirin in COVID-19: Pros and Cons

et al. 2022

View full text Add to dashboard Cite

Since its emergence, the COVID-19 pandemic has been ravaging the medical and economic sectors even with the significant vaccination advances. In severe presentations, the disease of SARS-CoV-2 can manifest with life-threatening thromboembolic and multi-organ repercussions provoking notable morbidity and mortality. The pathogenesis of such burdensome forms has been under extensive investigation and is attributed to a state of immune dysfunction and hyperinflammation. In light of these extraordinary circumstances, research efforts have focused on investigating and repurposing previously available agents that target the inflammatory and hematological cascades. Aspirin, due to its well-known properties and multiple molecular targets, and ought to its extensive clinical use, has been perceived as a potential therapeutic agent for COVID-19. Aspirin acts at multiple cellular targets to achieve its anti-inflammatory and anti-platelet effects. Although initial promising clinical data describing aspirin role in COVID-19 has appeared, evidence supporting its use remains fragile and premature. This review explores the notion of repurposing aspirin in COVID-19 infection. It delves into aspirin as a molecule, along with its pharmacology and clinical applications. It also reviews the current high-quality clinical evidence highlighting the role of aspirin in SARS-CoV-2 infection.

show abstract

Section: Clinical Uses Of Aspirinmentioning

confidence: 99%

Aspirin in COVID-19: Pros and Cons

et al. 2022

View full text Add to dashboard Cite

show abstract

Phytohormones: Multifunctional nutraceuticals against metabolic syndrome and comorbid diseases

Kim

Goossens

Libert

et al. 2020

Biochemical Pharmacology

View full text Add to dashboard Cite

Metabolism of liver CYP450 and ultrastructural changes after long-term administration of aspirin and ibuprofen

Wen

Zhuang

Song

et al. 2018

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Worldwide, aspirin and ibuprofen are the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs). Some adverse reactions, including gastrointestinal reactions, have been concerned extensively. Nevertheless, the mechanism of liver injury remains unclear. In the present study, we focused on the metabolism of liver cytochrome P450 (CYP450) and ultrastructural morphology of liver cells. A total of thirty rats were divided into three groups of 10. Rats in the aspirin and ibuprofen groups were given enteric-coated aspirin (15 mg/kg) and ibuprofen (15 mg/kg), respectively by gavage for four weeks. The body weights were recorded every two days. Liver function and metabolic capacity of CYP450 were studied on days 14 and 28. We then conducted ultrastructural examinations. Body weights in the Ibuprofen group were lower than those of the Control group, and ALT and AST levels were significantly higher (P < 0.05). There were no significant differences in terms of body weight, ALT or AST between the Aspirin and Control groups. The metabolic capacity of CYP450 was evaluated using five probe drugs, phenacetin, tolbutamide, metoprolol, midazolam, and bupropion. We found that ibuprofen and aspirin induced metabolism of the probe drugs. Moreover, according to the pharmacokinetic data, the Control, Aspirin and Ibuprofen groups could be discriminated accurately. Ultrastructural examination showed that the number of mitochondria was increased in both the Ibuprofen and Aspirin groups. Long-term administration of enteric-coated aspirin and ibuprofen induced the metabolic activity of the CYP450 enzyme. Aspirin had better tolerability than did ibuprofen, as reflected by pharmacokinetic data of probe drug metabolism.

show abstract

Aspirin and the Treatment of Rheumatoid Arthritis

Cited by 11 publications

References 88 publications

Aspirin in COVID-19: Pros and Cons

Aspirin in COVID-19: Pros and Cons

Phytohormones: Multifunctional nutraceuticals against metabolic syndrome and comorbid diseases

Metabolism of liver CYP450 and ultrastructural changes after long-term administration of aspirin and ibuprofen

Contact Info

Product

Resources

About